Cargando…

Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies

Introduction: The immunogenicity of SARS-CoV-2 vaccines in patients with inflammatory bowel disease (IBD) on biologic therapies is not well studied. The goal of this study was to measure the serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD receiving different biolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Shehab, Mohammad, Alrashed, Fatema, Alfadhli, Ahmad, Alotaibi, Khazna, Alsahli, Abdullah, Mohammad, Hussain, Cherian, Preethi, Al-Khairi, Irina, Alphonse Thanaraj, Thangavel, Channanath, Arshad, Ali, Hamad, Abu-Farha, Mohamed, Abubaker, Jehad, Al-Mulla, Fahd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705736/
https://www.ncbi.nlm.nih.gov/pubmed/34960217
http://dx.doi.org/10.3390/vaccines9121471
_version_ 1784622020443504640
author Shehab, Mohammad
Alrashed, Fatema
Alfadhli, Ahmad
Alotaibi, Khazna
Alsahli, Abdullah
Mohammad, Hussain
Cherian, Preethi
Al-Khairi, Irina
Alphonse Thanaraj, Thangavel
Channanath, Arshad
Ali, Hamad
Abu-Farha, Mohamed
Abubaker, Jehad
Al-Mulla, Fahd
author_facet Shehab, Mohammad
Alrashed, Fatema
Alfadhli, Ahmad
Alotaibi, Khazna
Alsahli, Abdullah
Mohammad, Hussain
Cherian, Preethi
Al-Khairi, Irina
Alphonse Thanaraj, Thangavel
Channanath, Arshad
Ali, Hamad
Abu-Farha, Mohamed
Abubaker, Jehad
Al-Mulla, Fahd
author_sort Shehab, Mohammad
collection PubMed
description Introduction: The immunogenicity of SARS-CoV-2 vaccines in patients with inflammatory bowel disease (IBD) on biologic therapies is not well studied. The goal of this study was to measure the serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD receiving different biologic therapies. Methods: We performed a multi-center prospective study between 1 August 2021 and 15 September 2021. We measured the seropositivity of SARS-CoV-2 antibodies (SARS-CoV-2 IgG) and neutralizing antibody concentrations in patients with IBD receiving biologic therapies 4–10 weeks after their second dose or 3–6 weeks after their first dose of BNT162b2 or ChAdOx1 nCoV-19 vaccines. Results: A total of 126 patients were enrolled (mean age, 31 years; 60% male; 71% Crohn’s disease, 29% ulcerative colitis). Of these, 92 patients were vaccinated with the BNT162b2 vaccine (73%) and 34 patients with the ChAdOx1 nCoV-19 vaccine (27%). In patients being treated with infliximab and adalimumab, the proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving two doses of the vaccine were 44 out of 59 patients (74.5%) and 13 out of 16 patients (81.2%), respectively. In contrast, of those receiving ustekinumab and vedolizumab, the proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving two doses of the vaccine were 100% and 92.8%, respectively. In patients receiving infliximab and adalimumab, the proportion of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels after two-dose vaccination was 40 out of 59 patients (67.7%) and 14 out 16 patients (87.5%), respectively. On the other hand, the proportion of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels were 12 out of 13 patients (92.3%) and 13 out of 14 patients (92.8%) in patients receiving ustekinumab and vedolizumab, respectively. Conclusions: The majority of patients with IBD who were on infliximab, adalimumab, and vedolizumab seroconverted after two doses of SARS-CoV-2 vaccination. All patients on ustekinumab seroconverted after two doses of SARS-CoV-2 vaccine. The BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines are both likely to be effective after two doses in patients with IBD on biologics. Larger follow-up studies are needed to evaluate if decay of antibodies occurs over time.
format Online
Article
Text
id pubmed-8705736
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87057362021-12-25 Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies Shehab, Mohammad Alrashed, Fatema Alfadhli, Ahmad Alotaibi, Khazna Alsahli, Abdullah Mohammad, Hussain Cherian, Preethi Al-Khairi, Irina Alphonse Thanaraj, Thangavel Channanath, Arshad Ali, Hamad Abu-Farha, Mohamed Abubaker, Jehad Al-Mulla, Fahd Vaccines (Basel) Article Introduction: The immunogenicity of SARS-CoV-2 vaccines in patients with inflammatory bowel disease (IBD) on biologic therapies is not well studied. The goal of this study was to measure the serological response to BNT162b2 and ChAdOx1 nCoV-19 vaccines in patients with IBD receiving different biologic therapies. Methods: We performed a multi-center prospective study between 1 August 2021 and 15 September 2021. We measured the seropositivity of SARS-CoV-2 antibodies (SARS-CoV-2 IgG) and neutralizing antibody concentrations in patients with IBD receiving biologic therapies 4–10 weeks after their second dose or 3–6 weeks after their first dose of BNT162b2 or ChAdOx1 nCoV-19 vaccines. Results: A total of 126 patients were enrolled (mean age, 31 years; 60% male; 71% Crohn’s disease, 29% ulcerative colitis). Of these, 92 patients were vaccinated with the BNT162b2 vaccine (73%) and 34 patients with the ChAdOx1 nCoV-19 vaccine (27%). In patients being treated with infliximab and adalimumab, the proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving two doses of the vaccine were 44 out of 59 patients (74.5%) and 13 out of 16 patients (81.2%), respectively. In contrast, of those receiving ustekinumab and vedolizumab, the proportion of patients who achieved positive anti-SARS-CoV-2 IgG antibody levels after receiving two doses of the vaccine were 100% and 92.8%, respectively. In patients receiving infliximab and adalimumab, the proportion of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels after two-dose vaccination was 40 out of 59 patients (67.7%) and 14 out 16 patients (87.5%), respectively. On the other hand, the proportion of patients who had positive anti-SARS-CoV-2 neutralizing antibody levels were 12 out of 13 patients (92.3%) and 13 out of 14 patients (92.8%) in patients receiving ustekinumab and vedolizumab, respectively. Conclusions: The majority of patients with IBD who were on infliximab, adalimumab, and vedolizumab seroconverted after two doses of SARS-CoV-2 vaccination. All patients on ustekinumab seroconverted after two doses of SARS-CoV-2 vaccine. The BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines are both likely to be effective after two doses in patients with IBD on biologics. Larger follow-up studies are needed to evaluate if decay of antibodies occurs over time. MDPI 2021-12-13 /pmc/articles/PMC8705736/ /pubmed/34960217 http://dx.doi.org/10.3390/vaccines9121471 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Shehab, Mohammad
Alrashed, Fatema
Alfadhli, Ahmad
Alotaibi, Khazna
Alsahli, Abdullah
Mohammad, Hussain
Cherian, Preethi
Al-Khairi, Irina
Alphonse Thanaraj, Thangavel
Channanath, Arshad
Ali, Hamad
Abu-Farha, Mohamed
Abubaker, Jehad
Al-Mulla, Fahd
Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies
title Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies
title_full Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies
title_fullStr Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies
title_full_unstemmed Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies
title_short Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies
title_sort serological response to bnt162b2 and chadox1 ncov-19 vaccines in patients with inflammatory bowel disease on biologic therapies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705736/
https://www.ncbi.nlm.nih.gov/pubmed/34960217
http://dx.doi.org/10.3390/vaccines9121471
work_keys_str_mv AT shehabmohammad serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies
AT alrashedfatema serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies
AT alfadhliahmad serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies
AT alotaibikhazna serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies
AT alsahliabdullah serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies
AT mohammadhussain serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies
AT cherianpreethi serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies
AT alkhairiirina serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies
AT alphonsethanarajthangavel serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies
AT channanatharshad serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies
AT alihamad serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies
AT abufarhamohamed serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies
AT abubakerjehad serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies
AT almullafahd serologicalresponsetobnt162b2andchadox1ncov19vaccinesinpatientswithinflammatoryboweldiseaseonbiologictherapies